|1.||Sundar, Shyam: 5 articles (01/2014 - 02/2004)|
|2.||Hope, William W: 4 articles (05/2015 - 08/2005)|
|3.||Guarro, Josep: 4 articles (12/2009 - 07/2002)|
|4.||Wingard, John R: 4 articles (11/2005 - 08/2002)|
|5.||Harrison, Thomas S: 3 articles (12/2015 - 07/2013)|
|6.||Walsh, Thomas J: 3 articles (05/2015 - 10/2006)|
|7.||Goodwin, Joanne: 3 articles (05/2015 - 08/2010)|
|8.||Perfect, John R: 3 articles (01/2014 - 11/2004)|
|9.||Lortholary, Olivier: 3 articles (12/2009 - 08/2002)|
|10.||Pastor, F Javier: 3 articles (12/2009 - 12/2004)|
01/15/2004 - "Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections?"
03/01/2007 - "In spite of the development of new antifungal drugs, amphotericin B deoxycholate (d-AMB) remains the gold standard in the treatment of severe fungal infections in immunosuppressed hosts. "
06/01/2006 - "Amphotericin B deoxycholate has been the 'gold standard' treatment for invasive fungal infections for over 40 years. "
07/15/2004 - "Early trials of empirical antifungal therapy with amphotericin B deoxycholate (AmB) documented reductions in the frequency of and the morbidity and mortality associated with invasive fungal infections. "
02/01/2015 - "Amphotericin B deoxycholate nasal spray administered to hematopoietic stem cell recipients with prior fungal colonization of the upper airway passages is associated with low rates of invasive fungal infection."
03/01/2000 - "ABCD is approved by the US FDA for the treatment of invasive aspergillosis in patients where renal impairment of unacceptable toxicity precludes the use of amphotericin B deoxycholate in effective doses, and in patients with invasive aspergillosis where prior amphotericin B deoxycholate therapy has failed. "
05/01/2003 - "Described here are two cases of cerebral aspergillosis successfully treated with voriconazole after the failure of first-line treatment with amphotericin B deoxycholate. "
11/15/2005 - "In a previous randomized trial of voriconazole versus amphotericin B deoxycholate for primary therapy of invasive aspergillosis, voriconazole demonstrated superior efficacy and better survival. "
09/01/2004 - "The Global Comparative Aspergillosis study demonstrated that voriconazole, a new broad-spectrum triazole, had better responses and improved survival compared with conventional amphotericin B deoxycholate (CAB) and other licensed antifungal therapy (OLAT) for the treatment of definite or probable aspergillosis. "
05/01/2007 - "Despite the limitations inherent in a retrospective analysis of pooled studies, the response rates observed in this analysis were consistent with previous reports for antifungal therapy with amphotericin B deoxycholate or voriconazole in the treatment of invasive aspergillosis."
|3.||Visceral Leishmaniasis (Kala Azar)
08/01/2008 - "The aim of the present study was to compare the efficacy of a nano form of amphotericin B deoxycholate with that of conventional amphotericin B deoxycholate for the treatment of visceral leishmaniasis. "
11/01/2006 - "To identify and quantify the direct and indirect economic cost of treatment for visceral leishmaniasis (VL) with conventional Amphotericin B deoxycholate, currently the first-line treatment in Muzaffarpur. "
05/01/1999 - "Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases."
01/01/2014 - "With widespread resistance to pentavalent antimonial in the endemic eastern terai belt of Nepal and Bihar, India, Amphotericin B deoxycholate is now the first-line antileishmanial drug for the treatment of visceral leishmaniasis (VL). "
05/01/2009 - "Amphotericin B deoxycholate is used as a first-line drug for visceral leishmaniasis (VL) in India. "
12/01/2006 - "In patients with invasive candidiasis, it is as effective as amphotericin B deoxycholate. "
06/01/2000 - "In persistently leukopenic mice with severe invasive candidiasis, higher dosages of both hAMB-DOC and hcAMB-DOC were tolerated than those of conventional AMB-DOC (3 versus 0.8 mg/kg of body weight, respectively), resulting in significantly improved therapeutic efficacy. "
07/01/2005 - "In randomized clinical trials in patients with oropharyngeal/oesophageal and invasive candidiasis, caspofungin was at least as effective as amphotericin B deoxycholate, yet showed a significantly superior safety profile. "
12/19/2002 - "We performed a double-blind trial to compare caspofungin with amphotericin B deoxycholate for the primary treatment of invasive candidiasis. "
11/01/2012 - "Amphotericin B deoxycholate and fluconazole are most effective treatments for invasive candidiasis in infants."
07/22/2006 - "Amphotericin B deoxycholate is recommended as initial therapy for the empirical therapy in patients with neutropenia and persistent fever with close monitoring of adverse events."
09/18/2001 - "Amphotericin B deoxycholate is currently the standard empirical antifungal therapy in neutropenic patients with cancer who have persistent fever that does not respond to antibiotic therapy. "
03/01/2000 - "ABCD has been shown in a randomised, double-blind study, to be an effective alternative to amphotericin B deoxycholate for empirical treatment of patients with fever and neutropenia. "
09/01/2006 - "Intravenous itraconazole is as effective as amphotericin B deoxycholate and it is generally better tolerated than amphotericin B deoxycholate when it is given as empirical antifungal therapy for Korean patients with persistent neutropenic fever."
02/01/2014 - "We choose to determine the response of empirical amphotericin B deoxycholate (dAMB) starting either on day 4 or day 8 in febrile neutropenic patients not responding to broad-spectrum antibiotics and without localisation of fever. "
|1.||Amphotericin B (Amphotericin)
|2.||liposomal amphotericin B
|10.||phospholipid emulsion soybean oil (Intralipid)
|2.||Bone Marrow Transplantation (Transplantation, Bone Marrow)